Qualigen (QLGN) falls 5.52% for September 14

Equities Staff  |

Today, Qualigen Therapeutics Inc Inc’s (NASDAQ: QLGN) stock fell $0.08, accounting for a 5.52% decrease. Qualigen opened at $1.48 before trading between $1.48 and $1.36 throughout Tuesday’s session. The activity saw Qualigen’s market cap fall to $39,728,398 on 254,355 shares -below their 30-day average of 1,043,790.

About Qualigen Therapeutics Inc

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. The FastPack menu includes tests for cancer, men's health, hormone function and vitamin D status. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases, including COVID-19. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC.

Visit Qualigen Therapeutics Inc's profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Qualigen Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Qualigen Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

President Biden Hosting Leaders From India, Japan, Australia Friday in First 'Quad' Summit
Some Chinese Banks Stop Offering New Credit to Property Developers Amid Evergrande Scare
Iowa Senator Chuck Grassley Seeks Eighth Term of Office
House Select Committee Subpoenas Four Trump Allies in US Capitol Riot Probe
CDC Endorses COVID-19 Vaccine Booster Shots for Millions of Older and Vulnerable Individuals
Semiconductor Shortage To Cost Global Auto Industry $210 Billion in Revenue in 2021
US Olympic Athletes Must Have COVID-19 Vaccination for Beijing Winter Games
FAA Urges Airlines To Take Stronger Action With Unruly, Disruptive Passengers



Market Movers

Sponsored Financial Content